IRX Therapeutics is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer
IRX Therapeutics, Inc. is developing novel immunotherapies based upon reversing immune suppression that is typically seen in patients with cancer and other diseases. Our lead product, IRX-2, is a primary cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells, and natural killer cells.
IRX-2 has been studied in phase 1 and phase 2 trials. Analyses of the data from the phase 2 study suggest that IRX-2 is driving changes in the blood consistent with an anticancer immune response and that IRX-2 induces increased lymphocyte infiltration into HNSCC tumors, which is correlated with improved OS.1,2 Investigators have observed clinical responses.3,4
IRX-2 is now undergoing further clinical investigation in the IRX-2 Neoadjuvant Therapy in Head and Neck SCC to Provide Immune Response Enhancement (INSPIRE) study. This randomized, phase 2b study has been designed to determine whether neoadjuvant and adjuvant treatment with IRX-2 in newly diagnosed HNSCC beginning before curative surgery can reduce the risk of recurrence.
Learn more about how IRX Therapeutics is unlocking the power of immunotherapy with the objective of extending—and possibly saving—lives at risk from serious disease.
HNSCC, head and neck squamous cell cancer; OS, overall survival.